Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study-Reference-Cited by-同舟云学术

Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study

Published:2024-02 Issue:2 Volume:11 Page:e136-e146
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Abrisqueta Pau,González-Barca Eva,Panizo Carlos,Pérez José María Arguiñano,Miall Fiona,Bastos-Oreiro Mariana,Triguero Ana,Banerjee Lalita,McMillan Andrew,Seymour Erlene,Hirata Jamie,de Guzman Jayson,Sharma Sunil,Jin Hyun Yong,Musick Lisa,Diefenbach Catherine

Funder

F. Hoffmann-La Roche Ltd

Publisher

Elsevier BV

Reference28 articles.

1. Diffuse large B-cell lymphoma;Sehn;N Engl J Med,2021

2. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study;Crump;Blood,2017

3. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma;Sehn;J Clin Oncol,2020

4. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial;Caimi;Lancet Oncol,2021

5. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial;Kalakonda;Lancet Haematol,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-mCD20 in combination with α-mCXCL13 monoclonal antibody inhibits anti-FVIII antibody development in hemophilia A mice;International Immunopharmacology;2024-09

2. A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers;Molecular Cancer;2024-03-23